Literature DB >> 27867630

MELK kinase holds promise as a new radiosensitizing target and biomarker in triple-negative breast cancer.

Carlos S Moreno1.   

Abstract

Entities:  

Year:  2016        PMID： 27867630      PMCID： PMC5107521          DOI： 10.21037/jtd.2016.10.40

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  14 in total

1.  A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.

Authors:  Yahong Wang; Quangui Yin; Qi Yu; Jing Zhang; Ziyu Liu; Shuling Wang; Shuhua Lv; Yun Niu
Journal:  Breast Cancer Res Treat       Date:  2011-08-12       Impact factor: 4.872

2.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

3.  Maternal embryonic leucine zipper kinase (MELK) reduces replication stress in glioblastoma cells.

Authors:  Cenk Kig; Monique Beullens; Lijs Beke; Aleyde Van Eynde; Johannes T Linders; Dirk Brehmer; Mathieu Bollen
Journal:  J Biol Chem       Date:  2013-07-08       Impact factor: 5.157

Review 4.  The Evolving Landscape of HER2 Targeting in Breast Cancer.

Authors:  Mark M Moasser; Ian E Krop
Journal:  JAMA Oncol       Date:  2015-11       Impact factor: 31.777

5.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

Authors:  M D Pegram; A Lipton; D F Hayes; B L Weber; J M Baselga; D Tripathy; D Baly; S A Baughman; T Twaddell; J A Glaspy; D J Slamon
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

6.  Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer.

Authors:  Corey Speers; Anna Tsimelzon; Krystal Sexton; Ashley M Herrick; Carolina Gutierrez; Aedin Culhane; John Quackenbush; Susan Hilsenbeck; Jenny Chang; Powel Brown
Journal:  Clin Cancer Res       Date:  2009-10-06       Impact factor: 12.531

7.  Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.

Authors:  Mary Jo Lund; Katrina F Trivers; Peggy L Porter; Ralph J Coates; Brian Leyland-Jones; Otis W Brawley; Elaine W Flagg; Ruth M O'Regan; Sheryl G A Gabram; J William Eley
Journal:  Breast Cancer Res Treat       Date:  2008-03-07       Impact factor: 4.872

8.  Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.

Authors:  Therese Sørlie; Yulei Wang; Chunlin Xiao; Hilde Johnsen; Bjørn Naume; Raymond R Samaha; Anne-Lise Børresen-Dale
Journal:  BMC Genomics       Date:  2006-05-26       Impact factor: 3.969

9.  EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner.

Authors:  Sung-Hak Kim; Kaushal Joshi; Ravesanker Ezhilarasan; Toshia R Myers; Jason Siu; Chunyu Gu; Mariko Nakano-Okuno; David Taylor; Mutsuko Minata; Erik P Sulman; Jeongwu Lee; Krishna P L Bhat; Anna Elisabetta Salcini; Ichiro Nakano
Journal:  Stem Cell Reports       Date:  2015-01-15       Impact factor: 7.765

10.  MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells.

Authors:  Yubao Wang; Young-Mi Lee; Lukas Baitsch; Alan Huang; Yi Xiang; Haoxuan Tong; Ana Lako; Thanh Von; Christine Choi; Elgene Lim; Junxia Min; Li Li; Frank Stegmeier; Robert Schlegel; Michael J Eck; Nathanael S Gray; Timothy J Mitchison; Jean J Zhao
Journal:  Elife       Date:  2014-05-20       Impact factor: 8.140
View more
  4 in total

1.  Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1.

Authors:  Lakshmi Reddy Bollu; Jonathan Shepherd; Dekuang Zhao; Yanxia Ma; William Tahaney; Corey Speers; Abhijit Mazumdar; Gordon B Mills; Powel H Brown
Journal:  NPJ Breast Cancer       Date:  2020-01-03

2.  The microRNAs miR-200b-3p and miR-429-5p target the LIMK1/CFL1 pathway to inhibit growth and motility of breast cancer cells.

Authors:  Dengfeng Li; Hong Wang; Hongming Song; Hui Xu; Bingkun Zhao; Chenyang Wu; Jiashu Hu; Tianqi Wu; Dan Xie; Junyong Zhao; Qiang Shen; Lin Fang
Journal:  Oncotarget       Date:  2017-07-12

3.  Bioinformatic analysis identifies potentially key differentially expressed genes in oncogenesis and progression of clear cell renal cell carcinoma.

Authors:  Haiping Zhang; Jian Zou; Ying Yin; Bo Zhang; Yaling Hu; Jingjing Wang; Huijun Mu
Journal:  PeerJ       Date:  2019-11-26       Impact factor: 2.984

4.  Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1.

Authors:  Lakshmi Reddy Bollu; Jonathan Shepherd; Dekuang Zhao; Yanxia Ma; William Tahaney; Corey Speers; Abhijit Mazumdar; Gordon B Mills; Powel H Brown
Journal:  NPJ Breast Cancer       Date:  2020-01-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.